An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme.
Phase of Trial: Phase II
Latest Information Update: 24 May 2018
At a glance
- Drugs Olaratumab (Primary) ; Ramucirumab (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 15 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Apr 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.